For Europe, Aduhelm Is Probably a No Go

Biogen’s Aduhelm (aducanumab) appears unlikely to receive a marketing authorization in the EU, after a European Medicines Agency expert panel issued a “negative trend” vote on the antiamyloid antibody.
Source: Drug Industry Daily